S1RA HCl
10mM in DMSO
- Product Code: 233908
CAS:
878141-96-9
| Molecular Weight: | 373.88 g./mol | Molecular Formula: | C₂₀H₂₃N₃O₂ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
S1RA HCl is primarily investigated for its potential in treating neuropathic pain due to its action as a selective sigma-1 receptor antagonist. By blocking sigma-1 receptors in the central nervous system, it modulates pain signaling pathways, particularly those involved in chronic and nerve-related pain conditions. This makes it a promising candidate for conditions such as diabetic neuropathy, chemotherapy-induced neuropathy, and other central sensitization pain states where conventional analgesics provide limited relief. Preclinical studies have shown that S1RA HCl can enhance the efficacy of opioids and reduce the development of tolerance, suggesting possible use in combination therapies for improved pain management with lower opioid doses. It does not act on opioid receptors, minimizing the risk of respiratory depression or addiction typically associated with opioid drugs. Research is ongoing to evaluate its safety and effectiveness in clinical settings.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 1ml | 10-20 days | $381.56 |
+
-
|
S1RA HCl
S1RA HCl is primarily investigated for its potential in treating neuropathic pain due to its action as a selective sigma-1 receptor antagonist. By blocking sigma-1 receptors in the central nervous system, it modulates pain signaling pathways, particularly those involved in chronic and nerve-related pain conditions. This makes it a promising candidate for conditions such as diabetic neuropathy, chemotherapy-induced neuropathy, and other central sensitization pain states where conventional analgesics provide limited relief. Preclinical studies have shown that S1RA HCl can enhance the efficacy of opioids and reduce the development of tolerance, suggesting possible use in combination therapies for improved pain management with lower opioid doses. It does not act on opioid receptors, minimizing the risk of respiratory depression or addiction typically associated with opioid drugs. Research is ongoing to evaluate its safety and effectiveness in clinical settings.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
$0.00
$0.00
Total :